Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 30:13:199-211.
doi: 10.2147/BCTT.S273058. eCollection 2021.

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer

Tara Hyder  1 , Saveri Bhattacharya #  2 , Kristine Gade #  3 , Azadeh Nasrazadani  3 , Adam M Brufsky  3
Affiliations
Review

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer

Tara Hyder et al. Breast Cancer (Dove Med Press). .

Abstract

Neoadjuvant therapy is integral to the treatment of early-stage breast cancer. Goals of treatment include surgical downstaging of the tumor, rendering inoperable tumors resectable, and de-escalating axillary surgery in those with clinically positive nodes. Additionally, response to treatment provides important prognostic information regarding risk of recurrence and guides future adjuvant treatment. Although chemotherapy serves as the backbone of neoadjuvant treatment, an increased understanding of the tumor's clinical course as well as its molecular and genetic make-up aids in individualizing treatment and developing novel agents. This review summarizes current clinical approaches and the future direction to the management of breast cancer patients in the neoadjuvant setting.

Keywords: breast-conserving surgery; neoadjuvant chemotherapy; neoadjuvant endocrine therapy; pCR.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Treatment algorithm for adjuvant treatment in HER2+ patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583 - DOI - PubMed
    1. Asselain B, Barlow W, Bartlett J, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)30777-5 - DOI - PMC - PubMed
    1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;2001(30):96–102. doi:10.1093/oxfordjournals.jncimonographs.a003469 - DOI - PubMed
    1. Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–2848. doi:10.1158/1078-0432.CCR-19-3492 - DOI - PMC - PubMed
    1. Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441–1446. doi:10.1245/s10434-015-4404-8 - DOI - PubMed

LinkOut - more resources